Black Diamond Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Black Diamond Therapeutics, Inc. (Nasdaq: BDTX) will present an update on its progress at the 41^st Annual J.P. Morgan Healthcare Conference on January 12, 2023, at 9:00 a.m. PT in San Francisco. CEO David M. Epstein will lead the presentation, focusing on the company’s advancements in precision oncology therapies targeting oncogenic driver mutations in genetically defined cancers. Black Diamond's pipeline includes clinical-stage programs BDTX-1535 and BDTX-4933, aiming to address significant unmet medical needs.

CAMBRIDGE, Mass. and NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing MasterKey therapies designed to overcome limitations of existing therapies by targeting families of oncogenic driver mutations in patients with genetically defined cancers, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update on the Company’s progress at the 41^st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 9:00 a.m. PT in San Francisco, California.

A live webcast of the presentation can be accessed by visiting the investors relations section of the Company’s website at: www.blackdiamondtherapeutics.com. A replay of the webcast will also be available and archived for 90 days following the event.

About Black Diamond
Black Diamond Therapeutics is a clinical-stage precision oncology medicine company focused on the development of MasterKey therapies that target families of oncogenic mutations in clinically validated targets. Black Diamond leverages a deep understanding of cancer genetics and onco-protein structure and function, to discover and develop innovative MasterKey therapies. The Company’s MasterKey therapies are designed to overcome resistance, minimize on-target, wild-type mediated toxicities, and be brain penetrant to address significant unmet medical needs of patients with genetically defined cancers. The Company is advancing a robust pipeline with lead clinical-stage program BDTX-1535, targeting MasterKey mutations in both EGFR mutant-positive non-small cell lung cancer (NSCLC) and in glioblastoma multiforme (GBM), and BDTX-4933, a program targeting RAF MasterKey mutations in solid tumors, as well as discovery-stage research programs. The Company’s proprietary Mutation-Allostery-Pharmacology, or MAP drug discovery engine, is designed to allow Black Diamond to analyze population-level genetic sequencing tumor data and validate MasterKey mutations.

Contact:
Julie Seidel, Stern Investor Relations
(212) 362-1200
investors@bdtx.com
media@bdtx.com

FAQ

What is Black Diamond Therapeutics presenting at the J.P. Morgan Healthcare Conference on January 12, 2023?

Black Diamond Therapeutics will present an update on its progress in developing precision oncology therapies.

Who is the CEO of Black Diamond Therapeutics?

David M. Epstein is the President and CEO of Black Diamond Therapeutics.

What is the focus of Black Diamond's MasterKey therapies?

MasterKey therapies target families of oncogenic driver mutations in patients with genetically defined cancers.

Where can I access the webcast of Black Diamond's presentation?

The live webcast can be accessed on Black Diamond's investor relations page.

What are the lead clinical-stage programs of Black Diamond Therapeutics?

The lead programs are BDTX-1535 and BDTX-4933, targeting specific mutations in non-small cell lung cancer and solid tumors.